Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Earn FY2024 Earnings of ($3.01) Per Share

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Analysts at Capital One Financial issued their FY2024 earnings per share estimates for Outlook Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. Capital One Financial analyst T. Chiang expects that the company will post earnings per share of ($3.01) for the year. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($4.08) per share. Capital One Financial also issued estimates for Outlook Therapeutics’ Q4 2024 earnings at ($0.86) EPS, FY2025 earnings at ($2.19) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at $2.74 EPS.

OTLK has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a report on Thursday. Chardan Capital restated a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Outlook Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $45.55.

Outlook Therapeutics Price Performance

Shares of NASDAQ:OTLK opened at $7.71 on Monday. Outlook Therapeutics has a 1-year low of $4.00 and a 1-year high of $29.20. The stock has a market cap of $180.49 million, a P/E ratio of -0.68 and a beta of 0.71. The firm has a fifty day moving average price of $7.68 and a 200 day moving average price of $8.05.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in OTLK. AQR Capital Management LLC acquired a new stake in Outlook Therapeutics in the second quarter valued at about $75,000. Squarepoint Ops LLC acquired a new position in Outlook Therapeutics during the 2nd quarter worth approximately $232,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter worth approximately $303,000. LVW Advisors LLC acquired a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at approximately $352,000. Finally, Rosalind Advisors Inc. purchased a new stake in shares of Outlook Therapeutics in the first quarter valued at approximately $3,723,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.